Skip to main content
Top
Published in: Endocrine Pathology 1/2015

01-03-2015

Parathyroid Adenoma in Patients with Graves’ Disease: a Report of 21 Cases

Authors: Shuanzeng Wei, Zubair W. Baloch, Virginia A. LiVolsi

Published in: Endocrine Pathology | Issue 1/2015

Login to get access

Abstract

Graves’ disease (GD) is frequently associated with mild hypercalcemia. The hypercalcemia may be due to the activation of osteoclastic bone resorption caused by the excess thyroid hormone. In some cases of GD, the hypercalcemia can be attributable to concomitant parathyroid diseases. In this study, 21 patients with a history of GD developed parathyroid adenoma based on histology, intraoperative parathyroid hormone (IOPTH) monitoring, and other clinical features. There were 11 patients with a history of radioactive iodine therapy (RAI) for GD. The latency time of RAI was from 12 to 41 years. The case cohort was divided into two groups: patients with (group GR: 11 patients) and patients without a history of RAI (group G: 10 patients). Mean age of patients in group GR was 54.8 years compared to 62.2 years of group G (P = 0.08). There were no statistically significant differences regarding the parathyroid weight, serum calcium, and pre- and post-parathyroidectomy PTH levels. There was no histopathologic difference between the two groups. In conclusion, we report 21 cases of parathyroid adenoma in patients with Graves’ disease. There may be a possible link between GD patients with a RAI history and an increased risk of parathyroid adenoma. The parathyroid adenomas showed no clinicopathological differences between GD patient with and without a history of RAI.
Literature
1.
go back to reference Nikiforov Y, Biddinger PW, Thompson LDR: Diagnostic pathology and molecular genetics of the thyroid. Baltimore, Md. ; Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009. Nikiforov Y, Biddinger PW, Thompson LDR: Diagnostic pathology and molecular genetics of the thyroid. Baltimore, Md. ; Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009.
2.
go back to reference Giovanella L, Suriano S, Ceriani L: Graves' disease, thymus enlargement, and hypercalcemia. The New England journal of medicine 2008, 358(10):1078–1079.CrossRefPubMed Giovanella L, Suriano S, Ceriani L: Graves' disease, thymus enlargement, and hypercalcemia. The New England journal of medicine 2008, 358(10):1078–1079.CrossRefPubMed
3.
go back to reference Iqbal AA, Burgess EH, Gallina DL, Nanes MS, Cook CB: Hypercalcemia in hyperthyroidism: patterns of serum calcium, parathyroid hormone, and 1,25-dihydroxyvitamin D3 levels during management of thyrotoxicosis. Endocrine practice 2003, 9(6):517–521.CrossRefPubMed Iqbal AA, Burgess EH, Gallina DL, Nanes MS, Cook CB: Hypercalcemia in hyperthyroidism: patterns of serum calcium, parathyroid hormone, and 1,25-dihydroxyvitamin D3 levels during management of thyrotoxicosis. Endocrine practice 2003, 9(6):517–521.CrossRefPubMed
4.
go back to reference Esselstyn CB, Jr., Schumacher OP, Eversman J, Sheeler L, Levy WJ: Hyperparathyroidism after radioactive iodine therapy for Graves disease. Surgery 1982, 92(5):811–813.PubMed Esselstyn CB, Jr., Schumacher OP, Eversman J, Sheeler L, Levy WJ: Hyperparathyroidism after radioactive iodine therapy for Graves disease. Surgery 1982, 92(5):811–813.PubMed
5.
go back to reference Kawamura J, Tobisu K, Sanada S, Okada Y, Yoshida O, Minami S, Hino M, Shigeno T, Konishi J, Morita R et al.: [Hyperparathyroidism after radioactive iodine therapy for Graves' disease: a case report]. Hinyokika kiyo Acta urologica Japonica 1983, 29(11):1513–1519.PubMed Kawamura J, Tobisu K, Sanada S, Okada Y, Yoshida O, Minami S, Hino M, Shigeno T, Konishi J, Morita R et al.: [Hyperparathyroidism after radioactive iodine therapy for Graves' disease: a case report]. Hinyokika kiyo Acta urologica Japonica 1983, 29(11):1513–1519.PubMed
6.
go back to reference Arem R, Lim-Abrahan MA, Mallette LE: Concomitant Graves' disease and primary hyperparathyroidism. Influence of hyperthyroidism on serum calcium and parathyroid hormone. The American journal of medicine 1986, 80(4):693–698.CrossRefPubMed Arem R, Lim-Abrahan MA, Mallette LE: Concomitant Graves' disease and primary hyperparathyroidism. Influence of hyperthyroidism on serum calcium and parathyroid hormone. The American journal of medicine 1986, 80(4):693–698.CrossRefPubMed
7.
go back to reference Xiao H, Yu B, Wang S, Chen G: Concomitant Graves' disease and primary hyperparathyroidism: the first case report in mainland of China and literature review. Chinese medical journal 2002, 115(6):939–941.PubMed Xiao H, Yu B, Wang S, Chen G: Concomitant Graves' disease and primary hyperparathyroidism: the first case report in mainland of China and literature review. Chinese medical journal 2002, 115(6):939–941.PubMed
8.
go back to reference Karakousis GC, Han D, Kelz RR, Nemani D, Karamacharya J, Roses R, Gimotty PA, Fraker DL: Interpretation of intra-operative PTH changes in patients with multi-glandular primary hyperparathyroidism (pHPT). Surgery 2007, 142(6):845–850; discussion 850 e841-842. Karakousis GC, Han D, Kelz RR, Nemani D, Karamacharya J, Roses R, Gimotty PA, Fraker DL: Interpretation of intra-operative PTH changes in patients with multi-glandular primary hyperparathyroidism (pHPT). Surgery 2007, 142(6):845–850; discussion 850 e841-842.
9.
go back to reference Baxter JD, Bondy PK: Hypercalcemia of thyrotoxicosis. Annals of internal medicine 1966, 65(3):429–442.CrossRefPubMed Baxter JD, Bondy PK: Hypercalcemia of thyrotoxicosis. Annals of internal medicine 1966, 65(3):429–442.CrossRefPubMed
10.
go back to reference Toursarkissian B, Sloan DA, Schwartz RW: Coexisting hyperthyroidism and primary hyperparathyroidism. Surgery 1993, 113(6):716–718.PubMed Toursarkissian B, Sloan DA, Schwartz RW: Coexisting hyperthyroidism and primary hyperparathyroidism. Surgery 1993, 113(6):716–718.PubMed
11.
go back to reference Abboud B, Sleilaty G, Mansour E, El Ghoul R, Tohme C, Noun R, Sarkis R: Prevalence and risk factors for primary hyperparathyroidism in hyperthyroid patients. Head & neck 2006, 28(5):420–426.CrossRef Abboud B, Sleilaty G, Mansour E, El Ghoul R, Tohme C, Noun R, Sarkis R: Prevalence and risk factors for primary hyperparathyroidism in hyperthyroid patients. Head & neck 2006, 28(5):420–426.CrossRef
12.
go back to reference Carlson D: Parathyroid pathology: hyperparathyroidism and parathyroid tumors. Archives of pathology & laboratory medicine 2010, 134(11):1639–1644. Carlson D: Parathyroid pathology: hyperparathyroidism and parathyroid tumors. Archives of pathology & laboratory medicine 2010, 134(11):1639–1644.
13.
go back to reference Baloch ZW, LiVolsi VA: Pathology of the parathyroid glands in hyperparathyroidism. Seminars in diagnostic pathology 2013, 30(3):165–177.CrossRefPubMed Baloch ZW, LiVolsi VA: Pathology of the parathyroid glands in hyperparathyroidism. Seminars in diagnostic pathology 2013, 30(3):165–177.CrossRefPubMed
14.
go back to reference Albrechtsen R, Bruun E, Hasner E, Visfeldt J: Parathyroid adenomas induced by radiation. Lancet 1977, 1(8016):854–855.CrossRefPubMed Albrechtsen R, Bruun E, Hasner E, Visfeldt J: Parathyroid adenomas induced by radiation. Lancet 1977, 1(8016):854–855.CrossRefPubMed
15.
go back to reference Triggs SM, Williams ED: Irradiation of the thyroid as a cause of parathyroid adenoma. Lancet 1977, 1(8011):593–594.CrossRefPubMed Triggs SM, Williams ED: Irradiation of the thyroid as a cause of parathyroid adenoma. Lancet 1977, 1(8011):593–594.CrossRefPubMed
16.
go back to reference Colaco SM, Si M, Reiff E, Clark OH: Hyperparathyroidism after radioactive iodine therapy. American journal of surgery 2007, 194(3):323–327.CrossRefPubMed Colaco SM, Si M, Reiff E, Clark OH: Hyperparathyroidism after radioactive iodine therapy. American journal of surgery 2007, 194(3):323–327.CrossRefPubMed
17.
go back to reference Rosen IB, Strawbridge HG, Bain J: A case of hyperparathyroidism associated with radiation to the head and neck area. Cancer 1975, 36(3):1111–1114.CrossRefPubMed Rosen IB, Strawbridge HG, Bain J: A case of hyperparathyroidism associated with radiation to the head and neck area. Cancer 1975, 36(3):1111–1114.CrossRefPubMed
18.
go back to reference Boehm BO, Rosinger S, Belyi D, Dietrich JW: The parathyroid as a target for radiation damage. The New England journal of medicine 2011, 365(7):676–678.CrossRefPubMed Boehm BO, Rosinger S, Belyi D, Dietrich JW: The parathyroid as a target for radiation damage. The New England journal of medicine 2011, 365(7):676–678.CrossRefPubMed
19.
go back to reference Rasmuson T, Tavelin B: Risk of parathyroid adenomas in patients with thyrotoxicosis exposed to radioactive iodine. Acta oncologica 2006, 45(8):1059–1061.CrossRefPubMed Rasmuson T, Tavelin B: Risk of parathyroid adenomas in patients with thyrotoxicosis exposed to radioactive iodine. Acta oncologica 2006, 45(8):1059–1061.CrossRefPubMed
20.
go back to reference Szabo E, Lundgren E, Juhlin C, Ljunghall S, Akerstrom G, Rastad J: Double parathyroid adenoma, a clinically nondistinct entity of primary hyperparathyroidism. World journal of surgery 1998, 22(7):708–713.CrossRefPubMed Szabo E, Lundgren E, Juhlin C, Ljunghall S, Akerstrom G, Rastad J: Double parathyroid adenoma, a clinically nondistinct entity of primary hyperparathyroidism. World journal of surgery 1998, 22(7):708–713.CrossRefPubMed
Metadata
Title
Parathyroid Adenoma in Patients with Graves’ Disease: a Report of 21 Cases
Authors
Shuanzeng Wei
Zubair W. Baloch
Virginia A. LiVolsi
Publication date
01-03-2015
Publisher
Springer US
Published in
Endocrine Pathology / Issue 1/2015
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-014-9349-0

Other articles of this Issue 1/2015

Endocrine Pathology 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.